NMRA

Neumora TherapeuticsA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-03

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$9.00

+417.2% vs current

Most likely

Base case

50%

Probability

Target price

$2.80

+60.9% vs current

B-

Bear case

30%

Probability

Target price

$0.60

-65.5% vs current

AI sentiment snapshot

Latest data as of 2026-06-03

AI commentary

Recent company updates keep a clear catalyst calendar in place, but coverage is thin and the packet does not provide consensus surprise data or post-print analyst revisions, so this remains a monitoring-first setup rather than a conviction-long thesis. Near-term trading should be dominated by the KOASTAL-2/-3 readout, while the May 7 update modestly reduces financing pressure by extending runway into 3Q27 [#SEC-8K-2026-05-07] [#PR-EARNINGS-2026-05-07].

RankAlpha Sentiment Codex - 2026-06-03

Open full AI memo

Evidence flagged

Coverage is limited for this name. This memo is usable, but confidence is lower and evidence depth is thinner than a standard report.

Impact

tentative

Confidence

AI events

2026-06-30eventKOASTAL-2 and KOASTAL-3 topline readoutHigh impact

Neumora said the navacaprant KOASTAL-2 and -3 studies were fully enrolled and remain on track for a joint topline readout in the second quarter of 2026, making this the main near-term rerating event for the stock [#SEC-8K-2026-05-07] [#PR-EARNINGS-2026-05-07].

2026-12-31catalystNMRA-511 MAD expansion data in Alzheimer’s disease agitationHigh impact

The May 7 business update said Neumora plans to report data from the NMRA-511 multiple ascending dose expansion cohort in the second half of 2026 after earlier Phase 1b results suggested activity and tolerability in Alzheimer’s disease agitation [#SEC-8K-2026-05-07] [#PR-EARNINGS-2026-05-07].

2026-12-31catalystNMRA-898 Phase 1/MAD data in schizophreniaHigh impact

Neumora is advancing NMRA-898 in a MAD study and expects data in the second half of 2026; constructive tolerability and CNS penetration data could broaden the pipeline narrative, but this remains an earlier-stage driver [#SEC-8K-2026-05-07] [#PR-EARNINGS-2026-05-07].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-06-03 • Updated nightlySource: Internal modelMethodology